An AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking comparable to that of international experts in prostate pathology. We may (will, in my view) use such technology to reduce pathology workload by reducing the assessment of benign biopsies and by automating the task of measuring cancer length in biopsy cores containing cancer.
Read more here:
ACTION PLAN: Sign up at the bottom of the blog page. Thanks!
understandcancerin60minutes 